69.76
price up icon1.69%   1.16
after-market Handel nachbörslich: 70.49 0.73 +1.05%
loading

Abivax Adr Aktie (ABVX) Neueste Nachrichten

pulisher
08:58 AM

Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating - TipRanks

08:58 AM
pulisher
03:00 AM

Abivax ADR Shows Rising Price Performance With Jump To 99 RS Rating - Investor's Business Daily

03:00 AM
pulisher
02:35 AM

Abivax (NASDAQ:ABVX) Hits New 52-Week High on Analyst Upgrade - Defense World

02:35 AM
pulisher
01:30 AM

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris - GlobeNewswire Inc.

01:30 AM
pulisher
Jul 23, 2025

Biotech Rockets Nearly 600% On 'Potentially Disruptive' News - Investor's Business Daily

Jul 23, 2025
pulisher
Jul 23, 2025

Prologis Inc (PLD) Stock: Navigating Drops and Gains - investchronicle.com

Jul 23, 2025
pulisher
Jul 23, 2025

Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment - TipRanks

Jul 22, 2025
pulisher
Jul 17, 2025

The ICU Stock Puzzle: Unraveling SeaStar Medical Holding Corp’s Fluctuating Performance - investchronicle.com

Jul 17, 2025
pulisher
Jul 14, 2025

Citizens JMP reiterates Market Outperform rating on Abivax stock - Investing.com India

Jul 14, 2025
pulisher
Jul 06, 2025

Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact - TipRanks

Jul 06, 2025
pulisher
Jul 04, 2025

Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment - TipRanks

Jul 04, 2025
pulisher
Jul 01, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jul 01, 2025
pulisher
Jun 27, 2025

Analyst Coverage Updates - The Globe and Mail

Jun 27, 2025
pulisher
Jun 12, 2025

Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Abivax SA Shareholders Approve 2024 Financials and Board Appointments - TipRanks

Jun 11, 2025
pulisher
Jun 10, 2025

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Galapagos (GLPG) and Tenet Healthcare (THC) - The Globe and Mail

Jun 10, 2025
pulisher
Jun 09, 2025

European ADRs Edge Up As Wisekey And ASML Lead Gains - Finimize

Jun 09, 2025
pulisher
Jun 04, 2025

Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst - TipRanks

Jun 04, 2025
pulisher
Jun 03, 2025

Abivax SA Reports Increased Losses Amid R&D Expansion - TipRanks

Jun 03, 2025
pulisher
Jun 02, 2025

Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs - TipRanks

Jun 02, 2025
pulisher
May 14, 2025

Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity - TipRanks

May 14, 2025
pulisher
Apr 29, 2025

Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials - TipRanks

Apr 29, 2025
pulisher
Apr 22, 2025

Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks

Apr 22, 2025
pulisher
Apr 18, 2025

Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister

Apr 18, 2025
pulisher
Apr 08, 2025

Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks

Apr 08, 2025
pulisher
Mar 27, 2025

Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 25, 2025

Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks

Mar 24, 2025
pulisher
Mar 18, 2025

Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks

Mar 17, 2025
pulisher
Mar 01, 2025

Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN

Mar 01, 2025
pulisher
Feb 24, 2025

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq

Feb 24, 2025
pulisher
Feb 11, 2025

Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance

Feb 11, 2025
pulisher
Feb 10, 2025

Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily

Feb 10, 2025
pulisher
Feb 10, 2025

Sibanye Stillwater Limited ADR (SBSW) rating downgrades by HSBC Securities - Knox Daily

Feb 10, 2025
pulisher
Feb 07, 2025

Quantum Corp (QMCO) Stock: A Closer Look at the Market Potential - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Analyzing the Price-to-Earnings Ratio of Abivax ADR (ABVX) - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Paylocity Holding Corp’s (PCTY) Stock: A Long-Term Performance Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Perrigo Company plc (PRGO) Stock: A Closer Look at the Moving Averages - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Analyzing the Price-to-Earnings Ratio of ICL Group Ltd (ICL) - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Tectonic Therapeutic Inc (TECX) Stock: A Review of the Recent Movement - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Healthcare Triangle Inc (HCTI) Stock: A Closer Look at the Market Potential - The News Heater

Feb 07, 2025
pulisher
Jan 30, 2025

Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks - MSN

Jan 30, 2025
pulisher
Oct 26, 2023

Citi Appointed as Depositary Bank for Abivax SA’s ADR Program - Business Wire

Oct 26, 2023
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Kapitalisierung:     |  Volumen (24h):